Cover Image
市场调查报告书

动脉硬化症的开发中产品分析

Arteriosclerosis - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品编码 245965
出版日期 内容信息 英文 59 Pages
订单完成后即时交付
价格
Back to Top
动脉硬化症的开发中产品分析 Arteriosclerosis - Pipeline Review, H2 2014
出版日期: 2014年07月31日 内容信息: 英文 59 Pages
简介

动脉粥状硬化性心血管疾病(atherosclerosis)是动脉硬化症(arteriosclerosis)的一种,但常常被直接误用,动脉粥状硬化性心血管疾病是指动脉壁内部或表面附著脂肪及胆固醇,形成Plaque(脉硬化斑块),而妨碍了血液流动的现象。

本报告提供全球各国治疗动脉硬化症用的开发中产品开发情形相关分析,汇整开发中产品的最新趋势,及临床实验各阶段产品一览,再加上主要企业简介,主要药物概要(产品概要,功能机制,研究开发(R&D)进展状况),最新的产业趋势等调查,并将结果概述为以下内容。

简介

  • 分析范围

动脉硬化症概要

治疗药的开发

  • 动脉硬化症开发中产品:概要
  • 动脉硬化症开发中产品:比较分析

各企业正开发中的动脉硬化症治疗药

大学/研究机关研究中的动脉硬化症治疗药

开发中产品概要

  • 后期阶段的产品
  • 临床实验阶段的产品
  • 初期阶段的产品

动脉硬化症治疗药:开发中产品一览(各企业)

动脉硬化症治疗药:研究中产品一览(大学/研究机关别)

动脉硬化症治疗药的开发企业

  • Johnson & Johnson
  • 兴和
  • 日本新药
  • KunWha Pharmaceutical Co., Ltd
  • AnGes MG, Inc.
  • LTT Bio-Pharma Co., Ltd
  • CytoTools AG
  • Angelini Group
  • ECI, Inc

动脉硬化症:治疗药的评估

  • 单剂治疗药的情况
  • 标的别
  • 各行动机制
  • 各投药法
  • 分子种类别
  • 各治疗分类

药物简介

  • beperminogene perplasmid
  • ecraprost
  • K-134
  • selexipag
  • beperminogene perplasmid
  • sarpogrelate SR
  • PPARgamma修饰药
  • 藉由腺病毒载体的人类ABCG1基因治疗
  • LT-0101
  • HMW02Ak
  • LMW-0x
  • FROUNT抑制剂
  • VE-Statin

动脉硬化症治疗药:最新的药物简介

动脉硬化症治疗药:暂停开发的产品

动脉硬化症治疗药:中止开发的产品

动脉硬化症相关产品的开发里程碑

  • 值得注意的最新趋势·新闻稿(全10件)

附录

图表一览

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GMDHC5260IDB

Summary

Global Markets Direct's, 'Arteriosclerosis - Pipeline Review, H2 2014', provides an overview of the Arteriosclerosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Arteriosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arteriosclerosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Arteriosclerosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Arteriosclerosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Arteriosclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Arteriosclerosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Arteriosclerosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Arteriosclerosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Arteriosclerosis Overview
  • Therapeutics Development
    • Pipeline Products for Arteriosclerosis - Overview
    • Pipeline Products for Arteriosclerosis - Comparative Analysis
  • Arteriosclerosis - Therapeutics under Development by Companies
  • Arteriosclerosis - Therapeutics under Investigation by Universities/Institutes
  • Arteriosclerosis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Arteriosclerosis - Products under Development by Companies
  • Arteriosclerosis - Products under Investigation by Universities/Institutes
  • Arteriosclerosis - Companies Involved in Therapeutics Development
    • Johnson & Johnson
    • Kowa Company, Ltd.
    • Nippon Shinyaku Co., Ltd.
    • KunWha Pharmaceutical Co., Ltd.
    • AnGes MG, Inc.
    • LTT Bio-Pharma Co., Ltd.
    • CytoTools AG
  • Arteriosclerosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • beperminogene perplasmid - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ecraprost - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • K-134 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • selexipag - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sarpogrelate SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LMW-0x - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Arteriosclerosis and Endothelial Dysfunction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-0101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VE-Statin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Arteriosclerosis - Recent Pipeline Updates
  • Arteriosclerosis - Dormant Projects
  • Arteriosclerosis - Discontinued Products
  • Arteriosclerosis - Product Development Milestones
    • Featured News & Press Releases
      • May 01, 2014: The Medicines Company and Alnylam Announce Presentation of New Pre-Clinical Data on PCSK9 at Arteriosclerosis, Thrombosis and Vascular Biology 2014 Scientific Sessions
      • Nov 15, 2012: AtheroNova Receives Notice Of Issuance Of U.S. Patent 8,304,383
      • Nov 02, 2012: AlphaCore Receives Orphan Drug Designation For ACP-501 From European Medicines Agency
      • Aug 26, 2012: Merck Provides Update On Tredaptive Development Program
      • Jul 09, 2012: AtheroNova Receives Notice Of Allowance For US Patent Application 12/024,908
      • Apr 25, 2012: Frontage Signs Agreement For Development Of Clinical Trial Supplies
      • Nov 02, 2011: Resverlogix Commences Dosing In ASSURE Phase IIb IVUS Clinical Trial Targeting High-Risk Cardiovascular Disease Patients
      • Mar 21, 2011: FDA Accepts Arisaph's Investigational New Drug Application For Dyslipidemia Drug
      • Jan 04, 2011: AnGes MG Announces Publication Of Collategene Clinical Research Data In Arteriosclerosis, Thrombosis And Vascular Biology
      • Jul 26, 2010: Cerenis And Novasep Receive EUR10.7 Million Funding From French Government For Development Of CER-001
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Arteriosclerosis, H2 2014
  • Number of Products under Development for Arteriosclerosis - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Late Stage Development, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • Arteriosclerosis - Pipeline by Johnson & Johnson, H2 2014
  • Arteriosclerosis - Pipeline by Kowa Company, Ltd., H2 2014
  • Arteriosclerosis - Pipeline by Nippon Shinyaku Co., Ltd., H2 2014
  • Arteriosclerosis - Pipeline by KunWha Pharmaceutical Co., Ltd., H2 2014
  • Arteriosclerosis - Pipeline by AnGes MG, Inc., H2 2014
  • Arteriosclerosis - Pipeline by LTT Bio-Pharma Co., Ltd., H2 2014
  • Arteriosclerosis - Pipeline by CytoTools AG, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Arteriosclerosis Therapeutics - Recent Pipeline Updates, H2 2014
  • Arteriosclerosis - Dormant Projects, H2 2014
  • Arteriosclerosis - Discontinued Products, H2 2014

List of Figures

  • Number of Products under Development for Arteriosclerosis, H2 2014
  • Number of Products under Development for Arteriosclerosis - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Target, H2 2014
  • Number of Products by Stage and Top 10 Target, H2 2014
  • Number of Products by Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
  • Number of Products by Top 10 Route of Administration, H2 2014
  • Number of Products by Stage and Top 10 Route of Administration, H2 2014
  • Number of Products by Top 10 Molecule Type, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top